Почетна › Меланом › Masachuset
Kliničke studije za Меланом u državi Masachuset
28 studija za Меланом traži učesnike na lokacijama u državi Masachuset.
Gradovi u državi Masachuset
Zvanični tekst studije (na engleskom)
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Call for Information (Investigational Site 0026), Boston
Тражи се учесникФаза 1/2
6 Months – 17 Years · Оба пола · Ажурирано 13. 11. 2026. · NCT02332668BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Baystate Medical Center, Springfield
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT05136196A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06150664A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- Local Institution - 0124, Boston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07492680Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Тражи се учесникФаза 2
Узраст од 18 до 100 · Оба пола · Ажурирано 28. 10. 2026. · NCT05428007Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
- Massachusetts General Hospital, Boston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 27. 10. 2026. · NCT07751042A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 9. 10. 2026. · NCT07070232Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Tufts Medical Center, Boston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 24. 9. 2026. · NCT06047379Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 9. 9. 2026. · NCT04899908DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
- Massachusetts General Hospital Cancer Institute, Boston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 9. 9. 2026. · NCT07288112Cryoablation+Ipilimumab+Nivolumab in Melanoma
- Massachusetts General Hospital Cancer Center, Boston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 27. 8. 2026. · NCT05779423Project: Every Child for Younger Patients With Cancer
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
- Baystate Medical Center, Springfield
- и још 1
Тражи се учесникОпсервациона студија
До 25 година · Оба пола · Ажурирано 25. 8. 2026. · NCT02402244Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Dana-Farber Cancer Institute, Boston
Тражи се учесникФаза 1/2
12 Months – 30 Years · Оба пола · Ажурирано 25. 8. 2026. · NCT04851119Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
- Massachusetts General Hospital, Boston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 14. 8. 2026. · NCT06425926A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Massachusetts General Hospital Cancer Center, Boston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 11. 8. 2026. · NCT05592626Integrated Cancer Repository for Cancer Research
- Holyoke Medical Center, Holyoke
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
Узраст од 19 до 110 · Оба пола · Ажурирано 29. 6. 2026. · NCT02012699Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Dana Farber Cancer Institute, Boston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 15. 5. 2026. · NCT05379985ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- Massachusetts General Hospital, Boston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 13. 5. 2026. · NCT03686124Neoadjuvant Darovasertib in Primary Uveal Melanoma
- Massachusetts General Hospital, Boston
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 6. 5. 2026. · NCT07015190A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
- Dana Farber, Boston
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 22. 4. 2026. · NCT06624644A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- Massachusetts General Hospital, Boston
Тражи се учесникФаза 2/3
Сви узрасти · Оба пола · Ажурирано 2. 4. 2026. · NCT06581406Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center (BIDMC), Boston
- Dana Farber Cancer Institute, Boston
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 25. 2. 2026. · NCT05549297ACTengine® IMA203 Combined With mRNA-4203
- Dana Farber Cancer Institute, Boston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 8. 1. 2026. · NCT06946225SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Worcester
Тражи се учесникОпсервациона студија
Сви узрасти · Оба пола · Ажурирано 28. 10. 2025. · NCT03452774A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 8. 10. 2025. · NCT04370587A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
- Massachusetts General Hospital, Boston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 13. 2. 2025. · NCT05669430Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
- Massachusetts General Hospital, Boston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 15. 11. 2024. · NCT04787042Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
- Dana Farber Cancer Institute, Boston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 18. 3. 2024. · NCT05280314Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.